Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

boehringer ingelheim (schweiz) gmbh - empagliflozinum - filmtabletten - empagliflozinum 25 mg, lactosum monohydricum 113 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 0.008 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, talcum, macrogolum 400, e 171, e 172 (flavum), pro compresso. - diabetes typ 2, prävention kardiovaskuläre ereignisse, herzinsuffizienz - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

boehringer ingelheim (schweiz) gmbh - empagliflozinum - filmtabletten - empagliflozinum 10 mg, lactosum monohydricum 162.5 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 0.01 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, talcum, macrogolum 400, e 171, e 172 (flavum), pro compresso. - diabetes typ 2, prävention kardiovaskuläre ereignisse, herzinsuffizienz - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozin - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - drogen bei diabetes verwendet - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 und 5. of the annex. heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure.  chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease.